Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Alkermes was filed in the last 90 days. The latest on record was on Nov 14, 2022.
How often do Alkermes insiders buy and sell shares?
Since 2011, Alkermes insiders reported 11 open-market purchases and 744 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2022.
Who is selling Alkermes stock?
In the last 90 days, 2 insiders of Alkermes (ALKS) reported 4 open-market sales worth $698K in total on SEC Form 4. The largest seller by value was Craig C. Hopkinson, with $423K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade ALKS?
Yes. Members of Congress disclosed 2 trades in Alkermes (ALKS) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
When does Alkermes report its next results?
Alkermes's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+59.4% (+$16.75) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $28.19 on Nov 20, 2025 to $44.94 on Nov 20, 2026 (+59.4%). Disclosed in this range: 2 insider trades, 31 pre-arranged insider sales, 2 Congress trades, and 16 13F position changes for 3 quarters ending in it.
$20$30$40$50$60$44.94
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 35 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Dublin, Ireland.
Last 12 months
+59.4%
S&P 500 +5.7% over the same dates
Market value
$7.55B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 19.6M shares sold short (11.7% of shares outstanding), +3.1% vs the previous count, 11.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$480M
+21.8% vs the same quarter a year earlier
Free cash flow, last 12 months
$227M
This quarter $90.1M, a year earlier $84.4M
Net debt
$880M
Debt $1.51B, cash $631M, at Sep 30, 2026
Net income, last 12 months
−$351K
Operating profit covers interest 0.741x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
On the public record for Alkermes over the 12 months to Nov 21, 2026: 9 clinical trials.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders. In the 30 days to Oct 26, 2026, Alkermes insiders filed 0 open-market purchases and 1 open-market sale. The largest sale was by David Joseph Gaffin, EVP, CLO, Alkermes, Inc., about $83K, filed Oct 2, 2026. Alkermes on OQRO
4 more points, with the facts they come from, are in OQRO Pro.
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Alkermes's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Alkermes's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insider buying and selling since 2011
Insiders of Alkermes reported 11 open-market purchases and 744 sales since 2011; purchases in 7 different years, most recently 2022.
Year
Bought
Sold
2026
—
$9.87M31×31 trades
2025
—
$16.3M14×14 trades
2024
—
$5.47M10×10 trades
2023
—
$2.25M4×4 trades
2022
$826K2×2 trades
$16.1M15×15 trades
2021
$314K2×2 trades
$16.9M21×21 trades
2020
$136K1×1 trade
$6.76M15×15 trades
2019
$142K2×2 trades
$19.8M22×22 trades
2018
—
$17.9M33×33 trades
2017
—
$25.2M65×65 trades
2016
$164K1×1 trade
$26.5M64×64 trades
2015
—
$76.2M130×130 trades
2014
$76K1×1 trade
$65.5M116×116 trades
2013
—
$52.1M116×116 trades
2012
$376K2×2 trades
$400M77×77 trades
2011
—
$2.81M11×11 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Red flags in its filings
Feb 25
Top officer leaving
“Pops, Chairman and Chief Executive Officer of Alkermes plc (the “Company”), notified the Company’s board of directors (the “Board”) of his decision to retire from his position of Chief Executive Officer, effective July 31, 2026, following a distinguished 35 years of service in this role.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Owners above 5%
No Schedule 13D or 13G filing on ALKS over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Late-stage clinical trials
6 active phase 3 trials and 3 active phase 2 trials led by this company, mostly in narcolepsy type 1, schizophrenia, idiopathic hypersomnia. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Since Nov 19, 2025, ALKS is up 56.6% and the index fund is up 4.1%: 53 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ALKS moves
A usual day
±1.4%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
3.8%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−7.1%Sep 18, 2026
Largest one-day rise
+17.3%Mar 31, 2026
Deepest fall of the year
−29.2%From the close of Jul 7, 2026 to Oct 14, 2026.
Days of 5% or more
10Out of 252 sessions, in either direction.
Beta 0.8(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Alkermes filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 33 open-market sales (about $10.1M, in 28 filings, by 7 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 17 open-market sales (about $19M, in 13 filings). (Alkermes on OQRO)
Congress. Members of Congress filed 2 disclosures on Alkermes in the 12 months to Nov 19, 2026: 2 purchases and 0 sales, by 1 member. In the 12 months before that: 0 disclosures. The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $15,001 to $50,000, filed Sep 4, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 8 new or larger positions and 8 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 9 studys sponsored by the company updated in the period; the latest, "A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attenti..." (Phase 2, status recruiting), was updated on Oct 29, 2026, with primary completion listed for 2027-07. FINRA short interest for ALKS on the settlement date of Oct 30, 2026 was 19,647,994 shares (+3.15% on the previous report), about 11.25 days of average volume.
Company reports, price and press. Alkermes filed a Form 8-K on Sep 16, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors. The company's own opening sentence of that report reads: "On September 14, 2026, the board of directors (the 'Board') of Alkermes plc (the 'Company') increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately..."
Who holds it. 421 funds reported a stake in Alkermes in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (16.4% of the value reported), BAKER BROS. ADVISORS LP (5.6% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.3% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Alkermes filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 33 open-market sales (about $10.1M, in 28 filings, by 7 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 17 open-market sales (about $19M, in 13 filings).
The largest sale: nancy lynn Md snyderman, Director, about $2.24M, filed Aug 3, 2026.
Congress
Members of Congress filed 2 disclosures on Alkermes in the 12 months to Nov 19, 2026: 2 purchases and 0 sales, by 1 member. In the 12 months before that: 0 disclosures.
The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $15,001 to $50,000, filed Sep 4, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 8 new or larger positions and 8 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 9 studys sponsored by the company updated in the period; the latest, "A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attenti..." (Phase 2, status recruiting), was updated on Oct 29, 2026, with primary completion listed for 2027-07.
FINRA short interest for ALKS on the settlement date of Oct 30, 2026 was 19,647,994 shares (+3.15% on the previous report), about 11.25 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Deep Track Capital, LP (increased, 409,677 shares); Holocene Advisors, LP (increased, 1,284,146 shares); the largest that shrank: Aviva PLC (sold out); Bleakley Financial Group, LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 3, 2026. Quarterly reports are not audited. Read the filing
By product or service
VIVITROL$128M
+5.3% on the same quarter a year earlier ($121M)
ARISTADA and ARISTADA INITIO$104M
+6.0% on the same quarter a year earlier ($98M)
LYBALVI$95.9M
−2.4% on the same quarter a year earlier ($98.2M)
LUMRYZ$89.9M
No figure for the same quarter a year earlier
For fiscal 2025, the company's proxy statement reported total compensation of $7.92M for its principal executive officer, and an average of $3.54M for the other named executive officers.
Company reports, price and press
Alkermes filed a Form 8-K on Sep 16, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On September 14, 2026, the board of directors (the 'Board') of Alkermes plc (the 'Company') increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately..."
Alkermes filed a Form 8-K on Aug 3, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On July 28, 2026, the Board took action to expand Mr. Jackson’s responsibilities and, commensurate with such expansion, to also appoint Mr. Jackson as President of the Company, effective August 1, 2026, and to approve Mr. Jackson..."
Alkermes filed a Form 8-K on May 20, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "On May 20, 2026, at the 2026 annual general meeting of shareholders (the 'Annual Meeting') of Alkermes plc (the 'Company'), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan t..."
Press coverage listed by Finnhub: "Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead" (Yahoo, Nov 16, 2026).
Press coverage listed by Finnhub: "Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress" (Yahoo, Nov 5, 2026).
Press coverage listed by Finnhub: "Alkermes plc 2026 Q3 - Results - Earnings Call Presentation" (SeekingAlpha, Nov 5, 2026).
ALKS closed at $46.85 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $42.97 to $46.85, a change of +9.0%.
Who holds it
421 funds reported a stake in Alkermes in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (16.4% of the value reported), BAKER BROS. ADVISORS LP (5.6% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Some lines are deducted from revenue, so no share of the total is shown; bars compare the size of each line.
The company also reports Product sales, net ($417M), Royalty ($63.2M), which group lines above and are not added again.
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 25, 2026. Read the filing
By product or service
VIVITROL$468M32%
+2.3% on the year before ($457M)
ARISTADA and ARISTADA INITIO$370M25%
+6.9% on the year before ($346M)
LYBALVI$347M23%
+24% on the year before ($280M)
Royalty$245M17%
−31% on the year before ($355M)
Manufacturing Revenue$46M3.1%
−61% on the year before ($119M)
Total revenue$1.48B−5.2%
The company also reports Product sales, net ($1.18B), Manufacturing and royalty revenues ($291M), which group lines above and are not added again.
By region
U.S.$1.37B93%
−2.7% on the year before ($1.41B)
Rest of world$102M6.9%
−30% on the year before ($146M)
Ireland$754K0.1%
−42% on the year before ($1.29M)
Total revenue$1.48B−5.2%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We have a portfolio of proprietary products that we manufacture, market and/or sell in the U.S., which in 2025 was comprised of ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. We also earned manufacturing and/or royalty revenues on net sales of products commercialized by our licensees, the most significant of which in 2025 were the long-acting INVEGA products and VUMERITY. We expect ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and VUMERITY, and our new product, LUMRYZ, which we acquired and began to market and sell in the U.S. in February 2026, to generate significant revenues for us in the near- and medium-term as we believe these products are singular or competitively advantaged products in their classes.
What the section covers (25 headings)
Overview
Business Update
Results of Operations
Product Sales, Net
Manufacturing and Royalty Revenues
Costs and Expenses
Cost of Goods Manufactured and Sold
Research and Development Expenses
Selling, General and Administrative Expenses
Other Income, Net
Income Tax Provision
Liquidity and Capital Resources
Sources and Uses of Cash
Operating Activities
And 11 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026 and Form 10-Q filed Nov 3, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Feb 25, 2026, compared with the one filed Feb 12, 2025. Read the filing
New risk factors in the latest annual report (4 headings)
We may fail to realize some or all of the anticipated benefits and synergies of the Avadel Acquisition or to successfully integrate Avadel’s business, which could adversely affect our business and financial condition and the price of our ordinary shares.
LUMRYZ is a controlled substance subject to U.S. federal and state-controlled substance laws and regulations, and any failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, could materially adversely affect our business, financial condition, cash flows and results of operations.
Our debt obligations could adversely affect our business and limit our ability to plan for or respond to changes in our business.
Changes in global trade or other policies, including tariffs or other restrictions imposed by the U.S. government or governments of other nations, could have an adverse effect on our business, results of operations, or financial condition.
Legal proceedings (Item 3)
For information regarding legal proceedings, refer to the discussion under the heading “Litigation” in Note 19, Commitments and Contingent Liabilities in the “Notes to Consolidated Financial Statements” in this Annual Report, which discussion is incorporated, in relevant part, into this Item 3 by reference.
Off-exchange trading: 46.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (31.0% on ATS, 15.7% with other brokers), above its 26-week average of 41.2%. Weeks of Sep 21 to Oct 16, 2026.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (13.4%), INTELLIGENT CROSS LLC (10.3%), SIGMA X2 (6.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.